Literature DB >> 18489860

Genetic determinants of drug response in heart failure.

Brian D Lowes1, Peter M Buttrick.   

Abstract

Heart failure management is complex and costly. Genetic variations that alter drug absorption, metabolism, and receptor-ligand interactions have the potential to modify drug response and safety. Evidence shows that genetic factors interact with numerous heart failure medications, including vasodilators, beta blockers, and angiotensin-converting enzyme inhibitors. Technologic advances will soon allow population-based genome-wide genetic testing at a reasonable cost. Understanding the genetic factors that influence drug response in heart failure will allow physicians to personalize therapies and optimize response while minimizing serious adverse events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489860     DOI: 10.1007/s11886-008-0031-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  45 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

Review 2.  Safety of statins: focus on clinical pharmacokinetics and drug interactions.

Authors:  Stefano Bellosta; Rodolfo Paoletti; Alberto Corsini
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

Review 3.  Structural variation in the human genome.

Authors:  Lars Feuk; Andrew R Carson; Stephen W Scherer
Journal:  Nat Rev Genet       Date:  2006-02       Impact factor: 53.242

Review 4.  Pharmacogenetics of beta-blockers.

Authors:  Jaekyu Shin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

5.  A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors.

Authors:  K M Small; S L Forbes; F F Rahman; K M Bridges; S B Liggett
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

6.  Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.

Authors:  David E Lanfear; Philip G Jones; Sharon Marsh; Sharon Cresci; Howard L McLeod; John A Spertus
Journal:  JAMA       Date:  2005-09-28       Impact factor: 56.272

7.  Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure.

Authors:  Dennis M McNamara; Richard Holubkov; Lisa Postava; Ravi Ramani; Karen Janosko; Michael Mathier; Guy A MacGowan; Srinivas Murali; Arthur M Feldman; Barry London
Journal:  Circulation       Date:  2003-03-17       Impact factor: 29.690

8.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

9.  Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.

Authors:  Zhuoqian Sun; Patrice M Milos; John F Thompson; David B Lloyd; Amy Mank-Seymour; Jodi Richmond; Jason S Cordes; Jun Zhou
Journal:  J Mol Cell Cardiol       Date:  2004-11       Impact factor: 5.000

10.  Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure.

Authors:  David M Kaye; Belinda Smirk; Carolyn Williams; Garry Jennings; Murray Esler; Dianne Holst
Journal:  Pharmacogenetics       Date:  2003-07
View more
  2 in total

1.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 2.  Toxicogenetics: population-based testing of drug and chemical safety in mouse models.

Authors:  Ivan Rusyn; Daniel M Gatti; Timothy Wiltshire; Timothy Wilshire; Steven R Kleeberger; David W Threadgill
Journal:  Pharmacogenomics       Date:  2010-08       Impact factor: 2.533

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.